LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, announced the issuance of two separate U.S. patents relating to the company’s monoclonal antibody therapeutics. Patents No. 7,435,415 and No. 7,435,554 are both entitled “Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC).” The inventions cover methods for the detection of certain specific epitopes in the SCLC patient and for treating those patients with the company’s monoclonal antibodies in a targeted manner. IMUC’s lead monoclonal antibody product candidate, ICT-109, which has demonstrated encouraging preliminary data in pre-clinical studies, is projected by IMUC to enter clinical trials in 2010 for SCLC and pancreatic cancer indications.
